HR+ HER2- Metastatic Breast Cancer:Yesterday. Today. Tomorrow.

ESMO ASIA 2017 INDUSTRY SATELLITE SYMPOSIUMSponsored by Pfizer Oncology

12:45–14:15 | Friday, 17 November 2017Room 325, Level 3, Suntec Singapore Convention & Exhibition Centre, Singapore Complimentary lunch will be provided to symposium attendees.

PROGRAM

Time Topic

12:45 Symposium welcome and faculty introduction

12:50 A molecular footprint: Where were we yesterday and today for mBC patients

13:05 A clinical footprint: Integrating CDK4/6 inhibitors in practice today and the evolving landscape

13:45 Asian experience with CDK4/6 inhibitors: A case study reflection

14:05 Rapid response panel discussion

14:15 Concluding remarks and session close

Interactive keypad voting will be conducted during this symposium.

Professor Hwai Loong, KongHL Kong Medical Oncology

Centre, Singapore

CHAIRPERSON

The symposium will be chaired by Professor HL Kong from HL Kong Medical Oncology Centre, Singapore.

We will also be joined by world-renowned international experts in breast cancer to discuss

the evolving landscape of HR+ HER2- mBC.

Further information is available from your local Pfizer representative.